A MAN is consoled by his relative as he sees the body of his father, who died from the coronavirus disease 2019 (COVID-19), before his burial at a graveyard in New Delhi, India, April 16. — REUTERS 

THE PHILIPPINES has detected its first two cases of a coronavirus variant first identified in India, the Department of Health (DoH) said on Tuesday. 

The variant, known as B.1.617, had been confirmed in two Filipino workers who returned in April from the United Arab Emirates and Oman, Alethea De Guzman, director of the DoH epidemiology bureau, told a news conference, adding they had been in isolation since coming back. 

In a bid to prevent the entry of variants, the Philippines has temporarily barred travelers coming from India, Pakistan, Sri Lanka, Nepal and Bangladesh from entering the country. 

India has recorded the world’s sharpest spike in coronavirus infections this month, with political and financial capitals New Delhi and Mumbai running out of hospital beds, oxygen and medicines. 

Scientists are studying what led to the unexpected surge, and particularly whether a variant of the novel coronavirus first detected in India is to blame. The variant, named B.1.617, has been reported in 17 countries, raising global concern. Here are the basics: 

WHAT IS THE INDIAN VARIANT?
The B.1.617 variant contains two key mutations to the outer “spike” portion of the virus that attaches to human cells, said senior Indian virologist Shahid Jameel. 

The World Health Organization (WHO) said the predominant lineage of B.1.617 was first identified in India last December, although an earlier version was spotted in October 2020. 

On May 10, the WHO classified it as a “variant of concern,” which also includes variants first detected in Britain, Brazil, and South Africa. Some initial studies showed the Indian variant spreads more easily. 

“There is increased transmissibility demonstrated by some preliminary studies,” Maria Van Kerkhove, WHO’s technical lead on coronavirus disease 2019 (COVID-19), said, adding it needs more information about the Indian variant to understand how much of it is circulating. 

ARE VARIANTS DRIVING THE SURGE IN CASES?
It’s hard to say. 

Laboratory-based studies of limited sample size suggest potential increased transmissibility, according to the WHO. 

The picture is complicated because the highly transmissible B.117 variant first detected in the UK is behind spikes in some parts of India. In New Delhi, UK variant cases almost doubled during the second half of March, according to Sujeet Kumar Singh, director of the National Centre for Disease Control. The Indian variant, though, is widely present in Maharashtra, the country’s hardest-hit state, Mr. Singh said. 

Prominent US disease modeler Chris Murray, from the University of Washington, said the sheer magnitude of infections in India in a short period of time suggests an “escape variant” may be overpowering any prior immunity from natural infections in those populations. 

“That makes it most likely that it’s B.1.617,” he said. But Mr. Murray cautioned that gene sequencing data on the coronavirus in India is sparse, and that many cases are also being driven by the UK and South African variants. 

Carlo Federico Perno, Head of Microbiology and Immunology Diagnostics at Rome’s Bambino Gesù Hospital, said the Indian variant couldn’t alone be the reason for India’s huge surge, pointing instead to large social gatherings. 

Prime Minister Narendra Modi has been criticized for allowing massive political rallies and religious festivals which have been super-spreader events in recent weeks. 

DO VACCINES STOP IT?
One bright spot is that vaccines may be protective. White House chief medical adviser Anthony Fauci said that preliminary evidence from lab studies suggest Covaxin, a vaccine developed in India, appears capable of neutralizing the variant. 

Public Health England said it was working with international partners but that there is currently no evidence that the Indian variant and two related variants cause more severe disease or render the vaccines currently deployed less effective. 

“We don’t have anything to suggest that our diagnostics, our therapeutics and our vaccines don’t work. This is important,” said Ms. Van Kerkhove at WHO. — Reuters